GT Biopharma is trading 8.57% up in pre-market at $0.30, after rising from the August 18, 2026 close of $0.28; no confirmed company-specific catalyst was identified for August 19, 2026.
- The latest major disclosure remains the August 14 second-quarter report and shareholder approval of a potential reverse split.
- Available market context shows only modestly weaker U.S. futures; the gain may reflect thin, volatile trading.